Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
80.37
-1.20 (-1.47%)
Jul 8, 2026, 4:00 PM EDT - Market closed
Halozyme Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 348.84 | 316.89 | 444.09 | 281.59 | 202.13 | 402.71 |
Depreciation & Amortization | 101.34 | 88.05 | 81.31 | 84.86 | 49.64 | 3 |
Stock-Based Compensation | 57.53 | 51.57 | 43.39 | 36.62 | 24.4 | 20.82 |
Other Adjustments | 14.03 | 347.31 | -0.45 | 24.17 | 52.39 | -130.07 |
Change in Receivables | -151.44 | -128.06 | -74.25 | -3.34 | -83.94 | 6.76 |
Changes in Inventories | 30.52 | 2.55 | -67.38 | -26.88 | -17.48 | 7.37 |
Changes in Accounts Payable | -27.93 | 6.21 | 46.99 | -12.55 | 24.54 | 1.17 |
Changes in Unearned Revenue | - | - | - | - | -2.49 | -0.75 |
Changes in Other Operating Activities | -37.07 | -32.96 | 5.36 | 4.1 | -9.06 | -11.56 |
Operating Cash Flow | 677.42 | 651.56 | 479.06 | 388.57 | 240.11 | 299.44 |
Operating Cash Flow Growth | 34.45% | 36.01% | 23.29% | 61.83% | -19.81% | 439.98% |
Capital Expenditures | -9.76 | -6.97 | -10.7 | -15.29 | -4.81 | -1.46 |
Sale of Property, Plant & Equipment | - | - | - | - | 26.01 | - |
Purchases of Investments | -116.56 | -247.36 | -647.6 | -292.91 | -255.21 | -652.52 |
Proceeds from Sale of Investments | 681.08 | 722.25 | 395.57 | 211.3 | 746.13 | 247.68 |
Payments for Business Acquisitions | 0.71 | -1,014 | - | - | -999.12 | - |
Investing Cash Flow | -458.27 | -545.81 | -262.72 | -96.91 | -487.01 | -406.29 |
Short-Term Debt Issued | - | - | - | - | 120 | - |
Short-Term Debt Repaid | - | - | - | - | -120 | - |
Long-Term Debt Issued | - | 1,470 | - | - | 250 | 784.88 |
Long-Term Debt Repaid | - | -763.39 | - | -13.48 | -327.45 | -369.06 |
Net Long-Term Debt Issued (Repaid) | - | 706.61 | - | -13.48 | -77.45 | 415.81 |
Issuance of Common Stock | 19.62 | 21.83 | 31.14 | 7.88 | 14.05 | 12.54 |
Repurchase of Common Stock | -190.63 | -342.37 | -250 | -392.38 | -200 | -350.06 |
Net Common Stock Issued (Repurchased) | -171.01 | -320.54 | -218.86 | -384.5 | -185.95 | -337.52 |
Other Financing Activities | - | -471.24 | - | - | 625.78 | -0.42 |
Financing Cash Flow | -83.47 | -85.17 | -218.86 | -407.99 | 362.37 | 77.87 |
Net Cash Flow | 135.68 | 20.57 | -2.52 | -116.33 | 115.48 | -28.98 |
Free Cash Flow | 667.65 | 644.59 | 468.37 | 373.28 | 235.3 | 297.98 |
Free Cash Flow Growth | 3.58% | 37.62% | 25.47% | 58.64% | -21.04% | 462.76% |
FCF Margin | 44.26% | 46.15% | 46.13% | 45.01% | 35.65% | 67.22% |
Free Cash Flow Per Share | 5.48 | 5.20 | 3.62 | 2.78 | 1.67 | 2.03 |
Levered Free Cash Flow | 405.94 | 1,080 | 499.68 | 302.34 | 165 | 816.29 |
Unlevered Free Cash Flow | 411.91 | 375.22 | 495.17 | 307.13 | 257.57 | 444.86 |